Seed Health has officially announced the launch of a new computational biology platform, which is designed to facilitate discovery and development of next-generation precision probiotics and microbiome-directed interventions. Powered by the world’s most comprehensive multi-omics data set in Human Phenotype Project, CODA comes decked up with an ability to expand upon previously unknown connections between the microbiome and health to develop targeted, outcome-specific interventions. More on its capabilities would reveal how the stated platform’s dataset integrates over three million phenotypic data points from more than 13,000 individuals across 40,000 cumulative subject years, combining microbiome analysis with genetic, immune, metabolomic, and proteomic data. Such a multi-dimensional approach should, on its part, prove useful when the agenda is to capture the diversity of human health factors, including biological, environmental, dietary influences, lifestyles, and medical histories, before clarifying critical interactions between the microbiome and host health. Eventually, this will reveal unique insights into the mechanisms underlying health and disease. To be more specific, CODA’s combinatorial dataset unlocks a new level of insight into the microbiome’s complex interactions with biological systems like the gut-brain, gut-heart, gut-liver, gut-skin, and gut-eye axes. Across these systems, the platform will support the development of organ-specific clocks, clocks that are going to reveal aging rates of different organs within the same individual.
Talk about the programs which CODA will operate at launch, they include a focus on cardiometabolic health, brain health, menopause, and longevity. Starting from cardiometabolic health, CODA will draw from one study which exposed a direct correlation between variations in microbial genes, body weight, and composition (based on 3,500 unique DEXA scans). It also works with a separate study that dug into how diet modifies metabolic parameters through microbiome modulation, highlighting a causal relationship. Using both the studies as its basis, CODA will develop consumer health products for tomorrow. Next up, we have the brain health program where CODA will investigate crucial links between the gut-brain and gut-eye axes so to understand how dietary compounds interact with the microbiome to impact brain health. By doing so, it will build upon those early findings that emphasize the significant role of microbial metabolites in brain development and function, thus paving the way for microbiome-targeted interventions to enhance neurocognitive health.
Moving on to CODA’s longevity program, this one is expected to generate an unprecedented level of insight into the distinction between biological and chronological age. Largely rooted in organ-specific functions and sex differences, the stated insight will help Seed Health to conceive targeted interventions to support immediate health, as well as long-term well-being and longevity. Finally, there is the menopause program, which will effectively use the discovery of a significant acceleration in Biological Age (BA) during menopause to provide a strong signal for targeted intervention. From a specific standpoint, the program in question will develop innovative solutions to mitigate menopause-induced symptoms and age acceleration.
“CODA enables the development of next-generation precision probiotics in a uniquely powerful way,” said Dirk Gevers, Ph.D., Chief Scientific Officer of Seed Health. “Rather than relying on a few biomarkers in isolation, CODA empowers us to examine them within a network of hundreds of other biological data points. This comprehensive approach allows us to unravel the complex interactions between diet, supplementation, the microbiome, and multi-system human health more effectively than before.”
